Glypican-3 antibody and uses thereof

An isolated anti-GPC3 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SEQ ID NO:

• 2 and the light chain variable region comprises SEQ ID NO:
• 4.

A method of imaging or visualizing a sample taken from a normal or malignant tissue, the method comprising contacting the sample with a labeled anti-GPC3 antibody or antigen-binding fragment thereof, wherein the anti-GPC3 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SEQ ID NO:

• 2 and the light chain variable region comprises SEQ ID NO:
• 4.

A method of inhibiting growth of a GPC3-expressing tumor cell, the method comprising contacting the tumor cell with an anti-GPC3 antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein an amino acid sequence of the heavy chain variable region comprises SEQ ID NO:

• 2 and the amino acid sequence of the light chain variable region comprises SEQ ID NO:
• 4.

An isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising a glypican-3 (GPC3) binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the isolated nucleic acid sequence that encodes the GPC3 binding domain comprises SEQ ID NO:

• 1 and SEQ ID NO:
• 3.

An isolated chimeric antigen receptor (CAR) comprising a GPC3 binding domain and a CD3 zeta signaling domain, wherein the GPC3 binding domain comprises SEQ ID NO:

• 2 and SEQ ID NO:
• 4.

A method of providing an anti-tumor immunity in a subject with a tumor that expresses glypican-3 (GPC3), the method comprising administering to the subject an effective amount of a genetically modified T cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) that comprises a glypican-3 (GPC3) binding domain, a 4-1BB co-stimulatory signaling domain, and a CD3 zeta signaling domain, wherein the GPC3 binding domain comprises SEQ ID NO:

• 2 and SEQ ID NO:
• 4.

A method of treating a glypican-3 (GPC3)-expressing liver cancer in a subject, the method comprising administering to the subject an effective amount of a genetically modified T cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) that comprises a GPC3 binding domain, a 4-1BB co-stimulatory signaling domain, and a CD3 zeta signaling domain, wherein the GPC3 binding domain comprises SEQ ID NO:

• 2 and SEQ ID NO:
• 4.